Trials / Unknown
UnknownNCT04253912
Topical 2% Povidone-Iodine Gel in Verruca Vulgaris
A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Veloce BioPharma LLC · Industry
- Sex
- All
- Age
- 8 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment. Subjects may have up to a total of 6 common warts located on their trunk or extremities that will be treated with study medication and followed throughout the study protocol therapy. All warts will be treated two times per day (BID) for12 weeks. Approximately 90 subjects will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBP-245 | 2% Povidone-Iodine Gel |
| DRUG | Placebo Gel (no Povidone-Iodine) | Placebo Gel (no Povidone-Iodine) |
Timeline
- Start date
- 2020-02-12
- Primary completion
- 2021-01-05
- Completion
- 2021-04-01
- First posted
- 2020-02-05
- Last updated
- 2021-04-01
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04253912. Inclusion in this directory is not an endorsement.